Functional Assessment of HDL: Moving Beyond Static Measures for Risk Assessment
Residual cardiovascular risk associated with low levels of HDL was a major theme at the American Heart Association’s 2009 Scientific Sessions. The presentations on HDL biology encompassed a broad spectrum of investigations that ranged from population-based studies, anti-atherothrombotic mechanisms of HDL particles, and therapeutic approaches to raising HDL cholesterol levels. This meeting highlight reviews some of the most important presentations that serve to enhance our knowledge in areas that extend beyond measurement of HDL cholesterol or apolipoprotein A-I concentration to precise mechanisms that elucidate functional aspects of HDL particles.
HDL cholesterol and cardiovascular risk
Low levels of HDL cholesterol are inversely related to the risk of coronary heart disease; however the additive contribution of HDL cholesterol and apolipoprotein A-I (apo A-I) in individuals with varying levels of LDL cholesterol (LDL-C) is less well established. In the Women’s Health...
Key wordsHigh density lipoprotein Cholesterol ester transfer protein Cholesterol ester transfer protein inhibitors Dalcetrapib Torcetrapib Niacin Cardiovascular disease
- 2.Frikke-Schmidt R et al. Cholesterol ester transfer protein genotype predicts anti-atherogenic lipid profile and decreased risk of ischemic heart disease, ischemic cerebrovascular disease, and death not attributable to HDL cholesterol alone. Circulation. 2009;120:S1175.Google Scholar
- 3.Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751–6.CrossRefPubMedGoogle Scholar
- 4.Vasquez E, Sethi AA, Sampson M, Remaly AT, Chaudry H. O Cannon III R. “Dysfunctional” high-density lipoprotein despite normal cholesterol content in sedentary obese women. Circulation. 2009;120:S470.Google Scholar
- 5.Khera AV, Rodriques A, de la Lioera-Moya M, Rothblatt GH, Rader DJ. Serum cholesterol efflux capacity, a measure of HDL-C quality, varies according to coronary artery disease status independently of HDL-C quantity. Circulation. 2009;120:S469.Google Scholar
- 6.Hara T, Ishida T, Kojima Y, Hirata K-I. Inactivation of endothelial lipase increases anti-inflammatory HDL particles. Circulation. 2009;120:S469.Google Scholar
- 7.Besler C, Heinrich K, Rohrer L, Yonekawa K, Doerriers C, Manes C, et al. Mechanisms leading to impaired endothelial-vasoprotective properties of high density lipoprotein (HDL) in patients with coronary disease (CAD). Circulation. 2009;120:S1009.Google Scholar
- 9.Drew BG, Duffy SJ, Forbes JM, Chin-Dusting J, Kaye DM, Kemp BE, et al. High density lipoprotein modulates glucose metabolism by multiple mechanisms. Circulation. 2009;120:S468.Google Scholar
- 13.Niesor EJ, Okamoto H, Naugeais C, von der Mark E, Brousse M, Blum-Kaelin D, et al. The effects of dalcetrapib on macrophage reverse cholesterol transport in a rodent model. Circulation. 2009;120:S468.Google Scholar